FiscalNote Holdings (NOTE) Q1 2025 Earnings Call May 12, 2025 05:00 PM ET Speaker0 Evening. My name is Pam, and I will be your conference operator today. At this time, I would like to welcome everyone to the FiscalNote Holdings Incorporated First Quarter twenty twenty five Financial Results Conference Call. Thank you. With that, I would now like to turn it over to the company to begin the conference. Speaker1 Good evening. My name is Bob Burrows, Investor Relations for FiscalNote, and we are pleased you all ...

Plug Power (PLUG) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Teal Vivacqua Hoyos - VP -Marketing & CommunicationsAndrew Marsh - CEOJose Crespo - Chief Revenue OfficerBill Peterson - Equity ResearchColin Rusch - Managing Director - Head of Sustainable Growth & Resource Optimization ResearchDushyant Ailani - Senior VP Conference Call Participants George Gianarikas - Managing Director and Senior AnalystEric Stine - Senior Research Analyst Operator Greetings, and welcome to the Plug Pow ...

Blink Charging (BLNK) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Vitalie Stelea - VP - Capital Markets and FP&AMike Battaglia - President & CEOMichael Rama - CFO Conference Call Participants Craig Irwin - Managing Director, Senior Research AnalystSameer Joshi - Senior Equity Research Analyst Operator Greetings. Welcome to the Blink Charge and Company's First Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. A question and answer sess ...

Gaia (GAIA) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Jirka Rysavy - Executive ChairmanJames Colquhoun - CEONed Preston - Chief Financial OfficerMark Argento - President & Co-Founder Conference Call Participants Alex Hantman - Analyst, Equity ResearchGeorge Kelly - Managing Director, Senior Research Analyst Operator Good afternoon. Welcome to Gaia's First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. Joining us today ...

Arrowhead Pharmaceuticals (ARWR) Q2 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Vincent Anzalone - Vice President, Investor RelationsChristopher Anzalone - President, CEO & Chairman of BoardBruce Given - Chief Medical ScientistAndy Davis - SVP of Cardiovascular & Head of Metabolic FranchiseDr. James Hamilton - Chief Medical OfficerKen Myszkowski - CFOPatrick Trucchio - Managing DirectorAndrea Newkirk - Biotechnolgy Equity ResearchMichael Ulz - Executive DirectorMayank Mamtani - Senior M ...

Radiant Logistics (RLGT) Q3 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Bohn Crain - Founder, CEO & ChairmanTodd Macomber - Senior VP & CFOJeffrey Kauffman - Partner & Transportation and Logistics Equity Research Conference Call Participants Elliot Alper - Analyst Operator Greetings, and welcome to the Radiant Logistics Third Quarter Fiscal Year twenty twenty five Earnings Call. At this time, all participants are on a listen only mode and a question and answer session will follow the fo ...

Neumora Therapeutics (NMRA) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Helen Rubinstein - VP-IR and Corporate CommunicationsPaul Berns - Co-Founder, Executive Chairman and Chief Executive OfficerJoshua Pinto - PresidentBill Aurora - Chief Operating & Development OfficerMichael Milligan - CFODouglas Tsao - Managing DirectorBrian Abrahams - MD & Global Sector Head - Health Care ResearchGraig Suvannavejh - Managing DirectorJohn Boyle - Biotechnology Equity Research AssociatePoorna Kann ...

Financial Data and Key Metrics Changes - The company recognized revenue of $7.5 million during Q1 2025, related to a milestone payment from a collaboration with Neurocrine [26] - Cash and cash equivalents totaled $691.1 million as of March 31, 2025, down from $754.4 million as of December 31, 2024 [26] - The company anticipates sufficient cash to fund operations into 2027, supporting multiple registrational programs [26][27] Business Line Data and Key Metrics Changes - The Phase three epilepsy program, particularly the EXTOL-two study, is nearing the end of patient recruitment, with top line results expected early next year [7][16] - The company is expanding its clinical development work in psychiatry, with ongoing enrollment in the Phase three MDD study X NOVA two and plans to initiate X NOVA three and a study in bipolar depression by mid-year [10][25] Market Data and Key Metrics Changes - The company highlighted a substantial need for new efficacious epilepsy therapies, particularly for patients experiencing focal seizures despite multiple anti-seizure medications [9] - There is excitement within the medical community regarding the potential of Ezetucalendar to address unmet needs in epilepsy treatment [9][19] Company Strategy and Development Direction - The company is focused on advancing its neuroscience pipeline, with a strong emphasis on the Zetu calendar for epilepsy and expanding its use into neuropsychiatry [5][15] - The company aims to transition from a clinical stage to a commercial organization, with positive Phase III results expected to enable an NDA submission to the FDA [27] Management's Comments on Operating Environment and Future Outlook - Management expressed high confidence in the EXTOL-two study's conduct and quality, despite a slight delay in timelines [16][46] - The company is optimistic about the potential of Ezetucalendar, citing positive feedback from the epilepsy community and ongoing educational outreach efforts [18][19] Other Important Information - The company plans to host multiple R&D webinars to showcase early-stage programs and engage with healthcare providers and patient advocacy groups [14] - The lead investigator of the MDD study intends to submit an abstract for presentation at the American Society of Clinical Psychopharmacology [24] Q&A Session Summary Question: Timeline for NDA filing after top line epilepsy data - Management indicated that it typically takes about six months from top line data to NDA filing, with clinical data being critical [30] Question: Patient recruitment status for EXTOL-two - Management noted that they are nearing completion of patient recruitment and expect to finish in the next couple of months [36][38] Question: Reasons for slight timeline slippage for EXTOL-two - Management described the delay as minor and attributed it to variability in patient recruitment across clinical sites [46] Question: Inclusion of bipolar I and II patients in studies - Management confirmed that both types will be included in the Phase III program, with plans to provide more detailed information soon [80][82] Question: Efficacy assessment for NAV1.1 in Dravet syndrome - Management emphasized the importance of addressing both seizure reduction and potential disease modification in their clinical development plan [66]

Getty Images (GETY) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Steven Kanner - Vice President of Investor Relations & TreasuryCraig Peters - Chief Executive OfficerJennifer Leyden - CFORonald Josey - Managing DirectorDanny Pfeiffer - Equity Research Associate Conference Call Participants Mark Zgutowicz - Equity Research Analyst Steven Kanner Before we begin, we would like to note that due to the ongoing regulatory review process, we will not be able to comment on the status of the m ...

Quanterix (QTRX) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Joshua Young - Head of Investor RelationsMasoud Toloue - CEOVandana Sriram - Chief Financial OfficerJake Allen - Healthcare Equity Research AssociatePuneet Souda - Senior MD Conference Call Participants Kyle Mikson - Managing Director & Senior Research AnalystSung Ji Nam - MD - Senior Healthcare AnalystDaniel Brennan - Senior Equity Research Analyst - Managing Director Operator Ladies and gentlemen, thank you for standing b ...